Posted July 21, 2026 Reviewed by Abigail Fagan Key points Scientific breakthroughs often begin with unexpected observations made while caring for patients
Shima Hadidchi, MD , is committed to guiding you on your journey to a healthier, more confident you
Injectable semaglutide and tirzepatide trials have shown average weight loss ranging from approximately 15% to 22% in different populations
The expression and distribution of FFARs such as GPR40, GPR119, and GPR120 in L and cells and glucose, along with their dual effects on insulin and GLP-1 secretion, have made them attractive therapeutic targets, leading to the development of agonists for these receptors for the treatment of T2DM [150,151,152,153,154]
IDOJ_187_17
GLP-1 is designed to support the bodys natural appetite signals, helping you feel fuller for longer and stay consistent with your nutrition plan